AFP2d
European Commission Approves the Extension of the Indication of Palforzia® to the Treatment of Toddlers With Confirmed Peanut Allergy
Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has approved the extension of indication of Palforzia® ...
The Globe and Mail15d
U.S. FDA approves injectable version of cancer drug from Bristol Myers Squibb
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb’s BMY-N blockbuster cancer drug, Opdivo. Opdivo is part of a class of ...
Federal Register15d
Modifications to Labeling of Buprenorphine-Containing Transmucosal Products for the Treatment of Opioid Dependence
This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the ...
New York Post18d
FDA approves Hikma’s generic version of Novo’s diabetes drug Victoza
Hikma said on Monday it was “pleased to have FDA approval to launch this important medicine and to provide broader access and greater affordability for the patients who rely on it”.
Medscape19d
The Evidence Gap: Immunotherapy Timing in Early-Stage NSCLC?
All the FDA-approved regimens are covered by insurance, said Chaft. Clinicians are most comfortable with pembrolizumab because it is the most widely used immunotherapy in advanced NSCLC ...
WebMD19d
FDA Approves Zepbound for Obstructive Sleep Apnea
Dec. 23, 2024 -- The FDA has approved the first prescription drug, Zepbound, for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Studies have shown that when ...
BioSpace19d
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
BRAFTOVI ® (encorafenib) is indicated, in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an ...
New Atlas20d
"100% successful" cancer drug gets landmark FDA approval
the FDA received 1,516 requests for this designation, and only 587 have been granted. This is in line with previous years, during which around 30-40% of requests have been approved. Dostarlimab ...
FiercePharma22d
A 'pivotal moment': Ionis enters next phase of commercial evolution with Tryngolza's FDA approval
With an FDA approval for Tryngolza (olezarsen) to treat the rare genetic disorder familial chylomicronemia syndrome (FCS), Ionis Pharmaceuticals enters a new era. While Ionis has gained several ...
clinicalpainadvisor.com22d
FDA to Review Sublingual Cyclobenzaprine for Fibromyalgia Management
TNX-102 SL is a non-opioid, centrally-acting analgesic administered at bedtime for the treatment of fibromyalgia. The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA ...